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Abstract
Alterations in glycosylation are seen in many types of cancer, including colorectal cancer
(CRC). Glycans, the sugar moieties of glycoconjugates, are involved in many important
functions relevant to cancer and can be of value as biomarkers. In this study, we have used
mass spectrometry to analyze the N-glycan profiles of 35 CRC tissue samples and 10
healthy tissue samples from non-CRC patients who underwent operations for other reasons.
The tumor samples were divided into groups depending on tumor location (right or left
colon) and stage (II or III), while the healthy samples were divided into right or left colon. The
levels of neutral and acidic N-glycan compositions and glycan classes were analyzed in a
total of ten different groups. Surprisingly, there were no significant differences in glycan lev-
els when all right- and left-sided CRC samples were compared, and few differences (such
as in the abundance of the neutral N-glycan H3N5) were seen when the samples were
divided according to both location and stage. Multiple significant differences were found in
the levels of glycans and glycan classes when stage II and III samples were compared, and
these glycans could be of value as candidates for new markers of cancer progression. In
order to validate our findings, we analyzed healthy tissue samples from the right and left
colon and found no significant differences in the levels of any of the glycans analyzed, con-
firming that our findings when comparing CRC samples from the right and left colon are not
due to normal variations in the levels of glycans between the healthy right and left colon.
Additionally, the levels of the acidic glycans H4N3F1P1, H5N4F1P1, and S1H5N4F1 were
found to change in a cancer-specific but colon location-nonspecific manner, indicating that
CRC affects glycan levels in similar ways regardless of tumor location.
Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide and has increased to
become the second most common cause of death due to cancer, with over 1.8 million new
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cases and almost 900 000 deaths estimated to occur in 2018 [1]. While incidence and mortality
rates are declining in certain countries, something thought to be at least partially due to early
screening and prevention, the incidence of CRC is still predicted to increase by up to 60% by
2030 [1, 2]. 5-year survival rates for CRC can be as high as 60% in countries such as the United
States, but are as low as 28% in developing countries [3].
The expression of glycans changes during cancer, and glycans are therefore of value as bio-
markers and targets for new treatments [4]. Glycans are covalent assemblies of sugars that can
exist either in free form as signaling molecules or as part of glycoconjugates such as glycopro-
teins. Most glycans exist as membrane-bound glycoconjugates [5]. They are found on all
eukaryotic cell surfaces and are involved in many physiologically important functions such as
cell signaling and adhesion, differentiation, and growth. Their complexity allows glycans on
cell surfaces to function as signaling, recognition, and adhesion molecules [6, 7]. Malignant
transformation is associated with changes in glycosylation, which include under- and overex-
pression of certain glycans, as well as neo-expression of glycans normally only expressed in
embryonic tissues. The changes in glycosylation most often seen that are associated with can-
cer include sialylation, fucosylation, and N-linked glycan branching [4, 8]. Several previous
studies have compared the serum/plasma asparagine-linked glycome (N-glycome) between
CRC patients and healthy controls [9, 10]. The N-glycome of CRC tissues in comparison to
healthy colon tissue has also been investigated in several studies. A study by Balog et al. found
that structures with a bisecting N-acetylglucosamine were decreased in CRC, while sulfated
glycans, paucimannosidic glycans, and sialylated Lewis type epitope-containing glycans were
increased. This study also detected core-fucosylated mannose N-glycans in CRC samples [11].
We have also previously shown that sialylated N-glycans, paucimannose glycans, and small
high-mannose type glycans are more common in rectal carcinomas than adenomas [12].
Multiple studies have found that right-sided colon cancer is associated with a worse prog-
nosis than left-sided colon cancer [13, 14]. Differences between cancer in the right and left
colon are also seen at the molecular level, with CRC in the right and left colon appearing to
progress through different molecular pathways, with mutations in genes such as KRAS and
BRAF being more common in right-sided tumors [15, 16]. Additionally, right- and left-sided
CRC also have distinct mutational profiles [17]. Studies have also found significant differences
in protein expression and plasma metabolites between patients with tumors in the right or left
colon [18–23].
In this study, we have used matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry to analyze the N-glycan profiles of 35 tumor tissue samples
from patients with CRC and 10 healthy colon tissue samples from patients who underwent
operation for other reasons. The tumor tissue samples were divided into groups according to
tumor location in the colon (right or left) and stage (II or III), while the healthy tissue samples
were divided into two groups, right and left colon. This study provides new insight into how
the levels of specific glycans and glycan classes differ depending on stage or location in the
colon, as well as between healthy tissue and tumor tissue samples.
Material and methods
Study design
In this study, the N-glycan profiles of formalin-fixed, paraffin-embedded (FFPE) tumor tissue
samples from 35 CRC patients and healthy colon tissue samples from 10 non-CRC patients
were analyzed using a previously developed workflow [12, 24–27]. CRC patients were chosen
according to the location and stage of their tumor. 18 patients had a tumor in the right colon
and 17 in the left colon, with the division being made at the splenic flexure. Besides comparing
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right- and left-sided CRC, the glycan profiles were also compared between patients with stage
II and III tumors.
Tissue samples
Tissue samples from 35 CRC patients were selected for glycomic profiling. Patients with deaths
due to reasons other than CRC were deliberately excluded from this study, as were patients
with a previous history of non-colorectal cancer, hereditary nonpolyposis colorectal cancer,
familial adenomatous polyposis, ulcerative colitis, Crohn’s disease, or celiac disease. In addi-
tion, 10 samples of healthy colon tissue from non-CRC patients were also selected. Five sam-
ples were from the right colon (caecum) and five from the left colon (sigma). These patients
had undergone operations due to different issues affecting the colon (see S1 Table for details).
The H&E slides of the tissue samples were confirmed by an experienced pathologist to be
either unaffected or lightly affected by the cause of operation, and to display either completely
or mostly normal histology. Patients with CRC were deliberately excluded when the healthy
tissue samples were chosen. Detailed patient characteristics can be found in S1 Table. All tissue
samples were routinely fixed and embedded in paraffin at the Department of Pathology, HUS-
LAB, Helsinki University Hospital, between 1996 and 2017. The Digital and Population Data
Services Agency provided the follow-up data, and Statistics Finland provided the cause of
death for all those deceased. This study was approved by the Surgical Ethics Committee of Hel-
sinki University Hospital (Dnro HUS 226/E6/06, extension TMK02 §66 17.4.2013) and was
carried out in accordance with the relevant guidelines and regulations. Written informed con-
sent was obtained from all participants prior to sample collection.
Glycan isolation
Glycans were isolated from FFPE tissue blocks as previously described [27]. To summarize, for
the tumor tissue samples from CRC patients, representative areas of carcinoma tissue were
marked on H&E slides and samples were punched from FFPE tissue blocks with a 3.0-mm
puncher. For the healthy colon tissue samples, 10 μm flakes were cut using a microtome. The
reason for using a microtome instead of a puncher for these samples was due to the better
yield of epithelial cells made possible by sectioning. Whereas the FFPE blocks for the tumor
tissue samples contained only tumor tissue, the samples from healthy colon tissue included
not only epithelial cells but also other layers of the colon.
All samples were deparaffinized with xylene and an ethanol-water series according to stan-
dard procedures. N-linked glycans were detached from cellular glycoproteins by N-glycosidase
F (PNGase F) digestion (Glyko; ProZyme Inc., Hayward, CA) and purified as previously
described [12]. Briefly, the detached glycans were passed in water through C18 silica, after
which they were absorbed to graphitized carbon material. Both of these steps were done in
96-well format. Next, the carbon wells were washed with water and neutral N-linked glycans
were eluted using 25% acetonitrile, while acidic N-linked glycans were eluted using 0.05% tri-
fluoroacetic acid in 25% acetonitrile in water. The acidic glycans were further purified through
hydrophilic interaction solid-phase extraction done in 96-well format. Both glycan fractions
were then passed in water through strong cation-exchange resin before MS analysis.
Mass spectrometry
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry
was performed using a Bruker Ultraflex III TOF/TOF mass spectrometer (Bruker Daltonics
Inc, Bremen, Germany) as previously described [27]. Neutral N-glycans were detected in posi-
tive ion reflector mode as [M+Na]+ ions and acidic N-glycans in negative ion reflector mode
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as [M-H]- ions. Two examples of unprocessed MALDI-TOF mass spectra of neutral and acidic
N-glycans are given in S1 Fig (neutral N-glycans) and S2 Fig (acidic N-glycans). The relative
molar abundances of neutral and acidic glycan components were assigned based on their rela-
tive signal intensities in the mass spectra when analyzed separately as neutral and acidic N-gly-
can fractions. The mass spectrometric raw data was transformed into the present glycan
profiles as previously described [24, 25]. The resulting glycan signals in the glycan profiles
were normalized to 100% to allow comparison between the samples and were assigned to bio-
synthetic groups based on their proposed monosaccharide composition, also as previously
described [24, 25]. The mass spectrometry proteomics data have been deposited to the Proteo-
meXchange Consortium via the PRIDE [28, 29] partner repository with the dataset identifier
PXD018673.
Analysis of N-glycan profiles
For the tumor tissue samples, N-glycan data was analyzed in different groups according to the
location of the tumor and tumor stage. Additionally, healthy tissue samples from the right and
left colon were analyzed and the glycan profiles were compared both separately and together
with the tumor tissue samples. Glycan abundance was analyzed separately within ten different
groups, as seen in Table 1. Both specific monosaccharide compositions, and structural glycan
classes were analyzed in these groups. The neutral and acidic N-glycan profiles were stratified
by biosynthetic classification rules based on the amounts of hexose (H), N-acetylhexosamine
(N), deoxyhexose (F), sialic acid (S), and sulfate/phosphate ester (P) residues in the proposed
monosaccharide compositions. The classes were then shown as the proportion of major glycan
structural classes between the different subgroups of samples.
Statistical analysis
For statistical analyses, the Mann-Whitney U test was used to analyze the values of the relative
intensities of the N-glycan signals in order to compare the differences between the groups. P-
values of< 0.05 were considered to be statistically significant. The false discovery rate (FDR)
was controlled using the Benjamini-Hochberg method [30]. The Mann-Whitney U test and
FDR correction were performed using SPSS version 24.0 (IBM SPSS Statistics, IBM Corpora-
tion, Armonk, NY). Orthogonal Projections to Latent Structures Discriminant Analysis
Table 1. The ten groups within which N-glycan abundances were analyzed in this study.
Number Group Size
1 Right-sided CRC vs. left-sided CRC 18 vs. 17
2 Right-sided CRC vs. left-sided CRC, stage II samples only 9 vs. 9
3 Right-sided CRC vs. left-sided CRC, stage III samples only 9 vs. 8
4 Stage II vs. III CRC, all samples 18 vs. 17
5 Stage II vs. III CRC, right-sided samples only 9 vs. 9
6 Stage II vs. III CRC, left-sided samples only 9 vs. 8
7 Healthy colon tissue, right vs. left 5 vs. 5
8 Right colon, healthy tissue vs. CRC 5 vs. 18
9 Left colon, healthy tissue vs. CRC 5 vs. 17
10 Healthy colon tissue vs. CRC, all samples 10 vs. 35
For each group, relative N-glycan abundance was analyzed separately for both neutral and acidic N-glycans. N-glycan
abundance was analyzed for the proposed monosaccharide compositions and, separately, for the proposed structural
classes of glycans.
https://doi.org/10.1371/journal.pone.0234989.t001
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(OPLS-DA) modeling was performed using the ropls [31] R package. For OPLS-DA modeling,
both neutral and acidic proposed monosaccharide compositions with non-FDR corrected p-
values of less than 0.05 were used in the same model.
Results
Glycomic profiling of colon cancer tissue samples
Neutral N-linked glycan profiles. The neutral N-linked glycan profiles of 35 CRC sam-
ples were analyzed using MALDI-TOF mass spectrometry. The levels of specific neutral N-gly-
can signals (assigned to proposed monosaccharide compositions) as well as the proposed
structural classes of neutral glycan signals were compared separately within all seven groups of
CRC patients studied, which are listed in Table 1. The neutral N-glycans expressed in the
group comparing samples from patients with stage II cancer in the right or left colon are
shown as the relative abundance of the 50 most abundant proposed monosaccharide composi-
tions in Fig 1. The monosaccharide compositions H5N2, H6N2, H8N2, H7N2, and H9N2,
which were classified as high-mannose N-glycans, were the most abundant neutral N-glycan
compositions in all groups analyzed.
Differences in glycan levels between right- and left-sided CRC. When the levels of neutral
monosaccharide compositions were analyzed according to tumor location (right or left colon),
only the abundance of one glycan, with the proposed monosaccharide composition H3N5,
was significantly different (p = 0.010) between the groups studied (all samples, stage II samples
only, and stage III samples only). The relative abundance of H3N5 was significantly higher in
Fig 1. The relative abundance of the 50 most abundant neutral monosaccharide compositions in samples from patients with stage II
cancer in the right (RC, blue bars, n = 9) or left (LC, orange bars, n = 9) colon. The x-axis shows the proposed neutral N-glycan
monosaccharide composition, where fucosylated and multifucosylated N-glycans are highlighted with green or red lines, respectively. The
results are shown as means ± SEM. Several putative N-glycan structures are depicted using symbols, with green circles representing D-
mannose, blue squares representing N-acetyl-D-glucosamine, red triangles representing L-fucose, and yellow circles representing D-
galactose. Major structural subgroups are separated by a dotted line. H = hexose, N = N-acetylhexosamine, F = fucose. Schematic glycan
drawings are proposed based on known glycan structures detected in CRC tissues [11] and they were not validated by structural analyses in
the present study.
https://doi.org/10.1371/journal.pone.0234989.g001
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left-sided stage II CRC when compared to right-sided stage II CRC (S2 Table). The neutral N-
glycan profiles were also analyzed by grouping glycans with similar monosaccharide composi-
tions into structural classes and calculating their combined proportions, similarly to as previ-
ously described [12, 25]. When the levels of these different classes of neutral glycans were
compared between right- and left-sided CRC, no statistically significant differences were
found (S3 Table). The abundances of the glycan classes were analyzed between all right- and
left-sided CRC samples regardless of stage, as well as separately for stage II and stage III
samples.
Differences in glycan levels between stage II and III CRC. The levels of neutral monosaccha-
ride compositions were also compared between all stage II and III samples, in right-sided sam-
ples only, and in left-sided samples only in order to study changes in glycan levels during CRC
progression. There were no statistically significant differences in the levels of either neutral N-
glycans (S2 Table) or neutral N-glycan classes (S3 Table) when samples from patients with
stage II and III CRC were compared.
Acidic N-linked glycan profiles. The profiles of acidic N-linked glycans, which contain
acid esters (sulfate or phosphate) or sialic acid residues, were analyzed separately from the neu-
tral N-glycans. The levels of specific acidic N-glycan signals as well as proposed structural clas-
ses of acidic glycans were compared separately within all seven groups of CRC patients studied
(Table 1), as was done for neutral N-glycans. The levels of acidic N-glycans when compared
between the groups stage II vs. III CRC, right-sided samples only (Fig 2) and stage II vs. III
Fig 2. The relative abundance of the 50 most abundant acidic monosaccharide compositions in samples from patients with stage II
(n = 9) or stage III (n = 9) cancer in the right colon. The x-axis shows the proposed acidic N-glycan monosaccharide composition, where
sulfated/phosphorylated N-glycans are highlighted with a light blue line and N-glycans putatively containing a terminal N-acetylhexosamine
(N>H) are highlighted with a dark blue line. The results are shown as means ± SEM. Several putative N-glycan structures are depicted using
symbols, with green circles representing D-mannose, blue squares representing N-acetyl-D-glucosamine, red triangles representing L-fucose,
yellow circles representing D-galactose, purple diamonds representing sialic acid (N-acetylneuraminic acid), and open circles marked with
an “S” representing sulfate ester. Major structural subgroups are separated by a dotted line. H = hexose, N = N-acetylhexosamine, F = fucose,
S = sialic acid, P = acid ester. Schematic glycan drawings are proposed based on known glycan structures detected in CRC tissues [11] and
they were not validated by structural analyses in the present study.
https://doi.org/10.1371/journal.pone.0234989.g002
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CRC, left-sided samples only (Fig 3) are shown as the relative abundance of the 50 most abun-
dant proposed monosaccharide compositions. The monosaccharide compositions S1H5N4F1,
S1H5N4, S2H5N4, S1H6N5F1, and S1H6N5F1, which were identified as sialylated complex-
type N-glycans, were often found to be the most abundant glycan signals in the groups
analyzed.
Differences in glycan levels between right- and left-sided CRC. When the levels of acidic
monosaccharide compositions were analyzed according to tumor location, regardless of stage,
no statistically significant differences between the levels of acidic N-glycans were found. The
levels of acidic glycans were also analyzed between right- and left-sided CRC for stage II and
III CRC samples separately, but no statistically significant differences were observed (S4
Table). The acidic N-glycan profiles were also analyzed by grouping glycans with similar
monosaccharide compositions into structural classes and calculating their combined propor-
tions, as previously described [12, 25] and as was done for the neutral N-glycans. When com-
paring the levels of the structural classes of acidic N-glycans between all right- and left-sided
samples and, separately, stage II samples only, no statistically significant differences were seen
(S5 Table). However, several statistically significant differences were seen between the levels of
three classes of acidic glycans when compared between right- and left-sided stage III CRC. The
levels of overall sialylation and sialylated complex-type N-glycans were significantly higher
(Table 2) in left-sided than right-sided stage III CRC (S5 Table). On the other hand, the relative
proportions of N-glycans with a sulfate/phosphate residue were significantly lower in left-
sided stage III CRC when compared to right-sided stage III CRC (S5 Table). OPLS-DA
Fig 3. The relative abundance of the 50 most abundant acidic monosaccharide compositions in samples from patients with stage II
(n = 9) or stage III (n = 8) cancer in the left colon. The x-axis shows the proposed acidic N-glycan monosaccharide composition, where
sulfated/phosphorylated N-glycans are highlighted with a light blue line and N-glycans putatively containing a terminal N-acetylhexosamine
(N>H) are highlighted with a dark blue line. The results are shown as means ± SEM. Several putative N-glycan structures are depicted using
symbols, as specified in the legend of Fig 2. Major structural subgroups are separated by a dotted line. Schematic glycan drawings are
proposed based on known glycan structures detected in CRC tissues [11] and they were not validated by structural analyses in the present
study.
https://doi.org/10.1371/journal.pone.0234989.g003
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modeling showed a clear separation between samples from patients with stage III cancer in the
right or left colon (S3 Fig).
Differences in glycan levels between stage II and III CRC. When the levels of acidic monosac-
charide compositions were compared between all stage II and III samples, significant differ-
ences in the levels of four glycans were seen (Table 3). The relative abundance of the sulfate/
phosphate-containing and multifucosylated structure H4N5F3P1 was higher in stage III CRC,
while the relative levels of the sialylated and multifucosylated structures S1H6N6F2,
S1H6N7F3, and S1H7N7F4 were lower in stage III CRC when compared to stage II CRC
(S4 Table). Interestingly, while the relative abundance of S1H7N7F4 was 0,25 in samples from
stage II CRC patients, this composition was not detected at all in any samples from stage III
patients. When focusing on samples from tumors in the right colon, the abundance of four
monosaccharide compositions was significantly different between stage II and III CRC
(Table 3).
The sulfate/phosphate-containing glycans H5N4F3P1, H4N5F3P1, H6N5F4P1, and
H9N8P1 all displayed higher relative levels in stage III CRC, indicating that the relative abun-
dance of these glycans changes when CRC progresses from local to regionally advanced disease
(S4 Table). In samples from the left colon, no statistically significant differences in the relative
levels of any acidic glycans were found between stage II and III CRC (S4 Table). Overall, more
differences were observed between the groups analyzed for acidic N-glycans than neutral N-
glycans. The levels of multiple monosaccharide compositions were significantly different
Table 2. Significantly different N-glycan classes (p < 0.05) when tumor tissue samples from CRC patients were compared.
Glycan class Group Neutral or acidic Fold change FDR-adjusted p-value
Overall sialylation Stage II vs III CRC, right-sided samples only Acidic 1,65 0,044
Overall sialylation Right-sided CRC vs. left-sided CRC, stage III samples only Acidic 1,67 0,037
Sialylated complex N-glycans Stage II vs III CRC, right-sided samples only Acidic 1,66 0,045
Sialylated complex N-glycans Right-sided CRC vs. left-sided CRC, stage III samples only Acidic 1,67 0,037
Sulfate/phosphate Stage II vs III CRC, right-sided samples only Acidic 2,40 0,044
Sulfate/phosphate Right-sided CRC vs. left-sided CRC, stage III samples only Acidic 2,43 0,037
Additional details can be found in S4 Table. The subgroup within which the levels of a glycan class are higher are highlighted in bold.
https://doi.org/10.1371/journal.pone.0234989.t002
Table 3. Significantly different proposed monosaccharide compositions (p< 0.05) when tumor tissue samples from CRC patients were compared.
Composition Group Neutral or acidic Fold change FDR-adjusted p-value
H3N5 Right-sided CRC vs. left-sided CRC, stage II samples only Neutral 4,66 0,01
H5N4F3P1 Right-sided CRC, stage II vs. III Acidic 5,43 0,009
H4N5F3P1 Stage II vs III CRC, all samples Acidic 5,27 0,043
H4N5F3P1 Right-sided CRC, stage II vs. III Acidic 9,04 0,022
H6N5F4P1 Right-sided CRC, stage II vs. III Acidic 6,16 0,009
S1H6N6F2 Stage II vs III CRC, all samples Acidic 4,31 0,044
S1H6N7F3 Stage II vs III CRC, all samples Acidic 15,18 0,038
H9N8P1 Right-sided CRC, stage II vs. III Acidic 6,02 0,019
S1H7N7F4 Stage II vs III CRC, all samples Acidic N/A 0,038
Additional details can be found in S1 and S3 Tables. The subgroup within which the levels of a specific monosaccharide composition are higher are highlighted in bold.
The fold change for the composition S1H7N7F4 is not available, as the relative abundance was 0.25 in stage II samples, while S1H7N7F4 was not detected at all in any of
the stage III samples (with a relative abundance of 0.00).
https://doi.org/10.1371/journal.pone.0234989.t003
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within two groups, namely stage II vs. III, all samples, and stage II vs. III, right-sided samples
only (S4 Table). The overexpression of the sulfate/phosphate-containing and multifucosylated
structure H4N5F3P1 was significant in both of these groups.
When comparing the classes of acidic N-glycans between all stage II and III samples regard-
less of tumor location, no statistically significant differences in the levels of acidic glycans were
seen (S5 Table). When the classes of acidic N-glycans were compared between stage II and III
right-sided CRC, significant differences between the relative proportions of the same three gly-
can classes whose levels differed between right- and left-sided stage III CRC (overall sialylation,
sialylated complex N-glycans, and N-glycans with a sulfate/phosphate residue) were seen
(Table 2). The relative levels of overall sialylation and sialylated complex N-glycans were signif-
icantly decreased in stage III right-sided CRC (S5 Table). On the other hand, the relative levels
of N-glycans with a sulfate/phosphate residue were significantly increased in stage III right-
sided CRC (S5 Table). When the relative levels of acidic glycan classes were compared between
stage II and III samples from the left colon, no statistically significant differences were found
(S5 Table). These results indicate that at least in right-sided CRC, cancer progression from
stage II to III is associated with significant changes in the abundance of certain classes of acidic
glycans.
Glycomic profiling of healthy colon tissue samples
Neutral N-linked glycan profiles. Healthy colon tissue samples from 10 patients were
also analyzed and the levels of neutral N-glycan compositions and glycan classes were com-
pared between samples from the right colon (n = 5) and left colon (n = 5). None of the differ-
ences in the levels of glycans and glycan classes were statistically significant after FDR
correction (S2 and S3 Tables).
Acidic N-linked glycan profiles. When the levels of acidic N-glycan compositions and N-
glycan classes were analyzed in healthy tissue samples from the right and left colon, no statisti-
cally significant differences were observed (S4 and S5 Tables).
Comparison of glycan profiles between healthy and tumor tissue
Neutral N-linked glycan profiles. When healthy tissue samples from the right colon were
compared with tumor tissue samples from the right colon, no significant differences were seen
in the levels of any neutral N-glycan compositions (S2 Table). However, the levels of fucosyla-
tion were significantly higher in tumor tissue samples from the right colon when compared to
healthy colon tissue (S3 Table). When healthy tissue samples from the left colon were com-
pared with tumor tissue samples from the left colon, the levels of 20 out of 126 neutral N-gly-
can compositions were significantly different between the two groups (S2 Table), and the
levels of paucimannose type N-glycans were significantly higher in tumor tissue samples (S3
Table). All healthy colon tissue samples were also compared to all CRC tissue samples. The lev-
els of 21 neutral N-glycan compositions were significantly different between the groups (S2
Table). Additionally, the levels of both paucimannose type N-glycans and fucosylation were
significantly higher in CRC samples than healthy colon tissue samples (S3 Table).
Acidic N-linked glycan profiles. When healthy tissue samples from the right colon were
compared with tumor tissue samples from the right colon, differences in the levels of five out
of 113 acidic N-glycan compositions were significant (S4 Table). Healthy tissue samples from
the left colon were also compared to tumor tissue samples from the left colon and significant
differences in the levels of 12 acidic N-glycan compositions were found (S4 Table). When all
healthy tissue samples were compared to all CRC samples, the levels of 74 of 113 acidic N-gly-
can compositions had significantly different levels between the two groups (S4 Table).
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Significant differences were seen in the same 11 out of 14 N-glycan classes when their levels
were compared between healthy colon tissue and tumor tissue samples in only samples from
the right colon, only samples from the left colon, and in all samples combined (S5 Table). Dif-
ferences include levels of complex fucosylation and sulfate/phosphate-containing N-glycans
being significantly higher in CRC when compared to healthy colon tissue, with levels of bian-
tennary-size N-glycans and sialylation being significantly lower in tumor tissue samples.
Discussion
In this study, we used MALDI-TOF MS to analyze the N-linked glycan profiles of 35 CRC tis-
sue samples from patients with right- and left-sided CRC that were also divided into groups
based on tumor stage (II or III). Due to the large number of monosaccharide compositions
detected, we used false discovery rate (FDR) correction to control false positive results in statis-
tical analyses. Surprisingly, there were no significant differences between the levels of neutral
and acidic N-glycans or structural N-glycan classes expressed when all right- and left-sided
CRC samples were compared. Only one neutral N-glycan, H3N5, displayed significantly dif-
ferent levels (p = 0.010) between right- and left-sided stage II CRC. The levels of overall sialyla-
tion, sialylated complex acidic N-glycans, and sulfated/phosphorylated glycans differed
between right- and left-sided stage III CRC, and these subgroups could be clearly separated
using OPLS-DA modeling (S3 Fig). Interestingly, these differences were only seen when sam-
ples were stratified according to stage, with no significant differences in glycan levels seen
between overall right- and left-sided CRC.
We found significant differences in the relative levels of four acidic N-glycans (H4N5F3P1,
S1H6N6F2, S1H6N7F3, and S1H7N7F4) between all stage II and III samples and in the relative
levels of four acidic N-glycans (H5N4F3P1, H4N5F3P1, H6N5F4P1, and H9N8P1) between
stage II and III samples from the right colon (S4 Table). H4N5F3P1 displayed significantly
higher levels in stage III CRC in both of the above groups, indicating that it may be linked to
CRC progression and regional metastasis. In left-sided tumors, the abundance of H4N5F3P1
also increased from stage II to III, but the increase was not significant. H4N5F3P1 therefore
has the potential to function as a target for new therapies after further investigation into its
role in CRC progression. The proposed monosaccharide composition of this glycan signal
comprises several interesting features, namely sulfation/phosphorylation (P), multifucosyla-
tion (F>1), and potential terminal N-acetylhexosamine (N>H), all of which have been previ-
ously linked to CRC [11, 12, 25]. Structural analysis of this glycan is thus warranted for
example in order to identify potential epitopes for anti-glycan antibody targeting.
Three structural classes of acidic N-glycans, overall sialylation, sialylated complex glycans,
and sulfated/phosphorylated glycans, also displayed significantly altered levels between stage II
and III CRC in the right colon (Table 2), indicating that these changes may be linked to cancer
progression. Further studies are needed to elucidate if these glycans play a role in regional
metastasis and if patients could benefit from new therapies targeting these glycans. Interest-
ingly, there were no significant changes in the levels of either neutral (S3 Table) or acidic (S5
Table) glycan classes when all stage II and III samples were compared. These findings indicate
that there are no widespread changes in classes of glycans during overall CRC progression,
despite the changes seen as right-sided CRC progressed from stage II to III.
In order to validate our findings that the levels of H3N5 and three acidic glycan classes dif-
fered between right- and left-sided CRC (in stage II and stage III samples, respectively), we
also analyzed healthy tissue samples from the right and left colon. There were no significant
differences in any of the neutral (S2 and S3 Tables) or acidic (S4 and S5 Tables) glycans and
glycan classes analyzed when these samples were compared. It is thereby possible to confirm
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that our findings when comparing tumor tissue samples from the right and left colon are not
due to normal variations in the levels of glycans between the healthy right and left colon. Addi-
tionally, the levels of acidic glycans such as H4N3F1P1, H5N4F1P1, and S1H5N4F1 were sig-
nificantly different when healthy tissue samples from the right or left colon were compared
with tumor tissue samples from the corresponding location, as well as when all healthy tissue
samples were compared to all tumor tissue samples. The levels of these three glycans did not
differ significantly when compared between healthy tissue samples from the right and left
colon, or when compared between CRC tissue samples from the right and left colon. These
results indicate that the changes in the levels of H4N3F1P1, H5N4F1P1, and S1H5N4F1 are
cancer-specific, although not colon location-specific.
Our findings suggest that while the normal right and left colon differ physiologically [16],
these differences do not appear to the same extent at glycan level, as there were no significant
differences in the relative levels of glycans or glycan classes between mass spectrometric N-gly-
can profiles when healthy tissue samples from the right or left colon were compared (S2–S5
Tables). It appears that CRC affects N-glycan profiles in similar ways regardless of where in
the colon the tumor arises, as we found that the relative proportions of the same 11 acidic gly-
can classes were significantly different when healthy tissue samples were compared to tumor
tissue samples both separately according to location in the colon (right or left) and when all
healthy samples were compared to all cancer samples (S5 Table). Additionally, no significant
differences were seen when N-glycan profiles were compared between all right- and left-sided
CRC samples, which lends further support to this hypothesis. It is known that cancer directly
affects glycan expression, which can also be seen in the large overall changes in relative N-gly-
can levels between healthy colon tissue and tumor tissue observed here, especially among
acidic glycans and glycan classes (S4 and S5 Tables), but also among neutral glycan composi-
tions (S2 Table) and, to a lesser extent, neutral glycan classes (S3 Table). These N-glycans and
N-glycan classes, whose relative levels significantly differ between healthy colon tissue and
CRC tissue, could be of value as new diagnostic markers and new targets for anticancer thera-
pies after further validation.
We have previously shown that N-glycomic profiling can be used to separate rectal adeno-
mas from carcinomas [12]. In that study, differences were seen in glycosylation between stage
I-II and stage III carcinomas, as well as between stage I-II and stage III-IV carcinomas. The
inclusion of adenomas and focus on comparing adenomas and carcinomas in our previous
study made comparisons to our current study difficult. However, some similarities were seen
between the two studies. The high-mannose type glycans H5N2, H6N2, H7N2, H8N2, and
H9N2, which were the most abundant neutral glycans in both rectal adenomas and carcino-
mas, were also the most abundant in carcinoma samples from the right and left colon. In our
previous study, acidic N-glycans with five N-acetylhexosamine residues (compositions con-
taining N5, such as H4N5F1P1 and H4N5F2P1) were more abundant in stage III than stage
I-II rectal carcinomas. In this study, while no significant differences were found between stage
II and III CRC samples from the left colon, changes in the relative levels of two glycans con-
taining N5, namely H4N5F3P1 and H6N5F4P1, were seen when right-sided stage II and III
samples were compared. This further indicates that acidic glycans containing N5 may play
roles in the progression of CRC from local to regional disease.
Several previous studies have investigated altered glycosylation in CRC. A study by Sethi
et al. reported an overrepresentation of high-mannose and paucimannose N-glycans in CRC
as compared to adjacent normal colon tissue [32]. Increased levels of mannose-type N-glycans
have been suggested to be a key molecular feature of CRC [33]. High-mannose type glycans
were also the most abundant neutral N-glycans in our set of 35 CRC tissue samples. Increased
sialylation has previously been implicated in CRC metastasis, therapeutic resistance, and
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disease recurrence [34–36]. In our study, sialylation was the most abundant acidic N-glycan
modification in most of the samples, except in right-sided stage III tumors, where sulfate/phos-
phate esters dominated. As mentioned earlier, a study by Balog et al. discovered that structures
with a bisecting N-acetylglucosamine were decreased in CRC as compared to corresponding
control tissue samples, while paucimannose glycans and glycans that could potentially contain
sialylated Lewis-type epitopes (sialylated glycans with at least two fucose residues) were
increased in CRC. In our current study, we found that the composition H5N5, whose pro-
posed structure contains a bisecting N-acetylglucosamine, as well as H3N6F2 and H3N6F3,
whose proposed structures contain a terminal N-acetylhexosamine, all had significantly lower
relative levels in CRC when tumor tissue samples were compared to healthy tissue samples
(S2 Table). Additionally, the relative levels of the paucimannosidic compositions H2N2F1 and
H3N2F1 were significantly higher in tumor tissue samples when compared to healthy colon
tissue samples (S2 Table). We also identified multiple compositions that could potentially con-
tain sialylated Lewis-type structures, including S1H4N5F2, S1H5N4F3, S1H5N5F2,
S1H6N5F2, S1H5N6F2, S1H7N6F3, and S1H7N6F4. The relative levels of all of these glycans
were significantly higher in tumor tissue samples when compared to healthy tissue samples
(S4 Table). These findings are all in concordance with the findings of Balog et al., further indi-
cating the importance of these glycans in CRC.
Multiple previous studies of the CRC N-glycome have utilized cell lines or serum/plasma
samples from patients [37–40]. This study was strengthened by the use of tumor tissue sam-
ples, which made it possible to directly study tumor-derived glycans and CRC progression. It
also enabled the correlation of changes in glycan levels to clinical stage. Additional strengths of
this study were the relatively large number of samples analyzed and the FDR correction used
to control false positives in the statistical analyses. One limit of this study is that although the
glycans were detached from tumor-derived glycoproteins, with the methods used, it is not pos-
sible to determine which specific cell types (e.g. cancer or stromal/immune cells) they origi-
nally came from. This study identified multiple glycans whose levels differed between stage II
and III CRC, which could be of value as biomarkers to predict disease progression, although
further validation is needed. For example, by staining tumor tissue samples from patients with
stage II for glycans whose levels were increased in stage III CRC, the risk of disease progression
could be predicted. These high-risk stage II patients could therefore benefit from more aggres-
sive treatment for example through adjuvant therapy, which is currently controversial for
stage II patients [41]. Additional studies are also needed to elucidate why these changes in gly-
can abundance occur, which proteins these glycans are attached to, and the effects of altered
glycan expression in CRC. This study provides new insights into the biological differences at
glycan level between healthy colon and tumor tissue, as well as between right- and left-sided
colon cancer and local and regional disease.
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S1 Fig. The unprocessed MALDI-TOF mass spectrum of neutral N-linked glycans isolated
from a tumor tissue sample from a patient with stage II cancer in the right colon.
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S2 Fig. The unprocessed MALDI-TOF mass spectrum of acidic N-linked glycans isolated
from a tumor tissue sample from a patient with stage II cancer in the right colon (the same
patient as in S1 Fig).
(PDF)
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stage III cancer in the right or left colon. For this model, both significantly different
(p< 0.05, non-FDR corrected) neutral and acidic proposed monosaccharide compositions
were used. The ellipses represent the 95% of the multivariate normal distributions for each
class shown.
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S2 Table. The relative abundance of the proposed neutral N-glycans detected in the CRC
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S4 Table. The relative abundance of the proposed acidic N-glycans detected in the CRC
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